查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969847

2026-2034年全球短腸症候群市場規模、佔有率、趨勢和成長分析報告

Global Short Bowel Syndrome Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 112 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，短腸症候群市場規模將從 2025 年的 19.2 億美元達到 40 億美元，2026 年至 2034 年的複合年成長率為 8.49%。

全球短腸症候群(SBS) 市場正穩定成長，主要受胃腸外科手術量增加以及克隆氏症和其他腸道疾病病例上升的推動。短腸症候群(SBS) 通常需要長期營養支持，包括腸外營養和特殊藥物治療。醫療專業人員對該疾病認知的提高以及診斷技術的進步，使得患者能夠及時接受治療。此外，生物療法和腸道復健計畫的進展也對市場成長產生了積極影響。

推動該市場發展的主要因素包括醫療保健支出不斷成長、標靶治療研發管線實力雄厚以及政府對罕見疾病的支持政策。製藥公司正投資研發能夠改善營養吸收並減少對腸外營養依賴的創新藥物。醫院基礎設施的改善和專科治療中心的普及也支撐了市場需求。已開發地區的患者支持計劃和報銷政策進一步加速了治療方案的推廣應用。

未來，先進的再生醫學和新型荷爾蒙療法有望推動市場發展。腸道適應療法和基於微生物組的解決方案的研究可能帶來新的成長機會。在新興經濟體，隨著醫療保健體系的擴展，治療的可近性有望得到改善。總體而言，持續的臨床研究和以患者為中心的創新將塑造短腸症候群市場的長期發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球短腸症候群市場：按類型分類

  • 市場分析、洞察與預測
  • GLP-2
  • 生長激素
  • 麩醯胺酸

第5章：全球短腸症候群市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 線上和線下藥局

第6章：全球短腸症候群市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • OxThera
    • Zealand Pharma
    • Ironwood Pharmaceuticals
    • Hanmi Pharm Co. Ltd
    • Jaguar Health
    • Merck KGaA
    • EnteraBio Ltd
    • NestlAfA（C）
    • Salix Pharmaceuticals
簡介目錄
Product Code: VMR112110467

The Short Bowel Syndrome Market size is expected to reach USD 4.00 Billion in 2034 from USD 1.92 Billion (2025) growing at a CAGR of 8.49% during 2026-2034.

The Global Short Bowel Syndrome Market is growing steadily due to the rising number of gastrointestinal surgeries and increasing cases of Crohn's disease and intestinal disorders. Short bowel syndrome (SBS) often requires long-term nutritional support, including parenteral nutrition and specialized drug therapies. Growing awareness among healthcare professionals and improved diagnosis are helping patients receive timely treatment. In addition, advancements in biologic therapies and intestinal rehabilitation programs are positively influencing market growth.

The main drivers of this market include increasing healthcare spending, a strong pipeline of targeted therapies, and supportive government policies for rare diseases. Pharmaceutical companies are investing in innovative drugs that improve nutrient absorption and reduce dependency on parenteral nutrition. Improved hospital infrastructure and access to specialized care centers are also supporting demand. Patient support programs and reimbursement policies in developed regions further boost treatment adoption.

In the future, the market is expected to benefit from advanced regenerative medicine and novel hormone-based treatments. Research in gut adaptation therapies and microbiome-based solutions may open new growth opportunities. Emerging economies are likely to see improved access to treatment as healthcare systems expand. Overall, continuous clinical research and patient-focused innovations will shape the long-term development of the Short Bowel Syndrome Market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • GLP-2
  • Growth Hormone
  • Glutamine

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

COMPANIES PROFILED

  • Takeda Pharmaceutical Company Limited, , OxThera, Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharm Co Ltd, Jaguar Health, Merck KGaA, EnteraBio Ltd, Nestl, Salix Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SHORT BOWEL SYNDROME MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. GLP-2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Growth Hormone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Glutamine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SHORT BOWEL SYNDROME MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Online & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SHORT BOWEL SYNDROME MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Distribution Channel
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Distribution Channel
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Distribution Channel
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Distribution Channel
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Distribution Channel
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SHORT BOWEL SYNDROME INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 OxThera
    • 8.2.2 Zealand Pharma
    • 8.2.3 Ironwood Pharmaceuticals
    • 8.2.4 Hanmi Pharm Co. Ltd
    • 8.2.5 Jaguar Health
    • 8.2.6 Merck KGaA
    • 8.2.7 EnteraBio Ltd
    • 8.2.8 NestlAfA(C)
    • 8.2.9 Salix Pharmaceuticals